BiotechTube
Home/Pipeline/VS41157

VS41157

Pancreatic Cancer

Preclinical/ClinicalActive

Key Facts

Indication
Pancreatic Cancer
Phase
Preclinical/Clinical
Status
Active
Company
Veroscience

About Veroscience

VeroScience, founded in 2003 and based in Raleigh, NC, is a private biotech leveraging circadian neuroendocrine science to develop novel therapeutics. The company's core platform, Circadian Neuroendocrine Resetting Therapy (CNRT), underpins its approved product for type 2 diabetes (Cycloset) and a pipeline exploring applications in pediatric diabetes and oncology. Operating as a small, efficient organization, VeroScience advances its programs through nationwide preclinical/clinical research and strategic academic and industry collaborations.

View full company profile

Therapeutic Areas

Metabolic DiseasesImmunological DisordersOncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b